TMBC Monthly Newsletter, Sept 2018, V20
|
|
Every month The Microbiome Coalition (TMBC) will bring you the latest in research, news and information to keep you up to date on the microbiome industry.
We welcome your feedback and suggestions for content.
Follow us on Twitter, @TMBCoalition
|
|
Exciting New TMBC Updates!
|
|
TMBC Regional Networking Event
San Francisco, October 2
Cole Hall Auditorium at the UCSF Parnassus Campus
6-8 pm
How does the microbiome impact moms and their babies?
On October 2 at the UCSF Parnassus campus, join the SF Microbiome Meet-up and The Microbiome Coalition (TMBC) for a night of networking and a panel discussion featuring Dr. Susan Lynch (UCSF Researcher and co-founder of Siolta Therapeutics), Dr. Nikole Kimes (Siolta Therapeutics) and Dr. David Kyle (CSO of Evolve Biosystems) about their work with the maternal and infant microbiome.
Refreshments and appetizers courtesy of Qiagen kick off at 6PM - we look forward to seeing you there! Please register at
Event Brite
If you are interested in sponsoring an event in one of these cities, or your city if is not listed and you'd like us to visit, please get in touch at
info@themicrobiomecoalition.com
|
|
FDA Workshop: Science and Regulation of Live Microbiome-Based Products Used to Prevent, Treat, or Cure Diseases in Humans.
The purpose of the public workshop is to exchange information with the scientific community about the clinical, manufacturing, and regulatory considerations associated with live microbiome-based products, when administered to prevent, treat, or cure a disease or condition in humans. The public workshop will bring together government agencies, academia, industry, and other stakeholders involved in research, development, and regulation of live microbiome-based products for such uses. Learn more
here
Synlogic Shows Positive Phase 1/2a Data in PKU.
Synlogic announced positive results from testing of a synthetically derived bacterial concoction designed to break down the amino acid phenylalanine that can can damage neurons in the brain, leading to delayed development, intellectual disability and psychiatric disorders. Full story
here
Vedanta Biosciences Appoints Dr. Susan Dillon to its Board of Directors.
Dr. Dillon is a recognized leader in the field of immunology who brings an impressive track record from her tenure at Janssen Research & Development. Dr. Dillon is Co-founder, President, and Chief Executive Officer of Aro Biotherapeutics, a biotechnology company focused on next generation protein medicines.
Full press release
here
|
|
Rethinking Probiotic Use, Causes Higher Prevalence of SIBO
.
A June 2018 study reporting higher incidences of SIBO and acidosis in some people who consume commercially available probiotics has support in a
new animal study that reports mice who consumed a commercial probiotic intended for human consumption experienced more severe infections linked to the intestinal parasite Cryptosporidium parvum.
Full article
here
Rethinking Probiotic Use, Mixed Colonization
.
Research out of the Weitzmann Institute suggests that commercially probiotic strains, although viable, have mixed results in colonizing the human gut, suggesting that benefits of taking probiotics are not as universal as thought.
Full studies
here
and
here
Time in Jungles of Amazon Changes Children's Microbiome, Not Adults'.
Immersion in the jungle can change a body for the better, but only if you’re between four and six years old. Tracking the
microbiomes
of city-dwellers over the course of a 16-day jungle experience, an international team of scientists led by Dr. Maria Gloria Dominguez-Bello showed that the two kids in the group came out with much more
diverse bacteria
in their bodies than they had previously, and that was a good thing. The five adults, however, came out mostly unchanged. Read more
here
Professor Christoph Thaiss, Ph.D Wins Agilent Early Career Professor Award.
Dr. Thaiss’s research at the University of Pennsylvania focuses on the microbiome and how it mediates the response of its host to environmental cues, which strongly influences the organism’s health and disease states. This research is also leading to work on potential translational outcomes, such as innovative therapies for common human diseases.
Learn more
here
Special Issue: Oncomicrobiome.
This special issue explores the rapidly evolving field of the microbiome and cancer. It consists of six articles from members of the International Cancer Microbiome Consortium which take readers through the technology and “omics” sciences underpinning microbiome research, including how the microbiome may cause cancer and the interaction of the microbiome with chemotherapeutics.
Read more
here
|
|
Mechanistic Microbiome Studies: Special Edition.
To highlight recent advances in the mechanistic understanding of microbiome function, eLife is pleased to present a Special Issue on this topic. This issue presents a collection of highly influential research relating to metagenomics, microbiota, and computational tools, as selected for publication by a specially convened group of experts.
Full edition
here
|
|
Principal Scientist, DMPK, Kintai
KINTAI THERAPEUTICS was founded by Flagship Pioneering in 2016 through its venture creation engine to pioneer therapeutics from microbiome metabolites. As a key member of the Kintai Therapeutics research and development team the Principal Scientist, DMPK will enable Kintai Therapeutics pioneering work in microbiome pharmacology. The candidate will lead the drug metabolism and pharmacokinetics team.
Learn more
here
Research Associate, Infectious Disease and Microbiome, Broad Institute
.
The Xavier Lab at the Broad Institute is looking for a Research Associate to contribute to its research on the role of the gut microbiome in health and disease. Learn more
here
Scientist, Microbiome, Seres Therapeutics.
Y
ou will use your training and education to develop quantitative methods, metrics, and analytical procedures for evaluating and interpreting microbiome datasets to identify disease targets and design Ecobiotic® therapeutics. Learn more
here
|
|
Grants, Competitions, Prizes, Opportunities
Mosaic Standards Challenge to Advance Microbiome Science.
Learn more
here
Participate in a Research Study: Microbiome Individuality and Stability Over Time.
A
Additional information and qualifications
here
|
|
JOIN TMBC
Members of TMBC participate on our committees, attend our events, generate networking and business development opportunities and, most importantly, contribute to the growth and success of a unique organization that is positioned to ensure that public opinion and policy pave the way for microbiome based therapeutics, diagnostics and direct-to-consumer services and products.
Membership Categories
• Sole proprietor (legal, consulting, other) • Academic and clinical institutions
• Patient advocacy groups • Industry/trade associations
• Corporations (pharmaceutical, diagnostic,bioinformatics, other)
Benefits of Membership
• Shape the Future of Microbiome Policy • Curated research library
• Monthly newsletter • White papers • Extended network • Job listings • Event listings
See our
flyer
for more details
|
|
Promoting Greater Understanding of the Role
of the Microbiome in Human Health and Wellness
|
|
|
|
|
|
|
